Reports Critically Low Cash Balance for 2025, Secures $2M Post-Year-End Financing to Fund Phase 3b ALS Trial

summarizeSummary

Brainstorm Cell Therapeutics reported a critically low cash balance at year-end 2025 but secured $2 million in post-year-end financing to support its Phase 3b ALS clinical trial, NurOwn.

check_boxKey Events

• Critically Low Cash Balance Reported

  The company reported cash, cash equivalents, and restricted cash of approximately $0.3 million as of December 31, 2025, indicating a precarious financial position.

• Significant Net Loss for 2025

  Brainstorm Cell Therapeutics recorded a net loss of approximately $10.3 million for the full year ended December 31, 2025, reflecting substantial ongoing operational expenses.

• Secured $2 Million Post-Year-End Financing

  Subsequent to year-end, in February 2026, the company entered into two strategic private placement agreements, securing a total of $2 million in funding to reinforce its valuation and support near-term operational objectives.

• Advancing Phase 3b ENDURANCE Study for NurOwn

  The company continues to execute on activities to support the planned Phase 3b ENDURANCE study of NurOwn for ALS, which received FDA clearance in 2025 and is designed to enroll approximately 200 participants.

auto_awesomeAnalysis

Brainstorm Cell Therapeutics reported a critically low cash balance of approximately $0.3 million as of December 31, 2025, alongside a net loss of $10.3 million for the year. This financial position highlights significant operational challenges for the company. However, the company subsequently secured $2 million in strategic private placement funding in February 2026, which is crucial for extending its cash runway and supporting near-term operational objectives, particularly the planned Phase 3b ENDURANCE study for NurOwn in ALS. The financing, while providing a temporary lifeline, underscores the company's ongoing need for capital to sustain its clinical development efforts. Investors should monitor the company's ability to manage its burn rate and secure further funding to complete its pivotal trial.